Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shakti Narain

Pulmonary Disease Leesburg, FL Medical Doctor

NPI 1689643199 CMS profile 121284

1070 Flagler Avenue, Leesburg, FL 34748

Open in the dashboard

General payments

$3,391

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shakti Narain of Leesburg, FL is reported in the CMS Open Payments database as having received $3,391 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $760 40
2024 General $452 26
2023 General $333 18
2022 General $622 32
2021 General $709 39
2020 General $116 8
2019 General $397 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shakti Narain
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Shakti Narain were reported at $760. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Shakti Narain Pulmonary Disease median Middle half National median
2019 $397 $377 $109–$1,340 $163
2020 $116 $230 $56–$907 $114
2021 $709 $269 $68–$1,072 $132
2022 $622 $390 $100–$1,457 $149
2023 $333 $419 $114–$1,659 $160
2024 $452 $476 $123–$1,818 $164
2025 $760 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,087 61 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $506 26 payments
  3. AstraZeneca Pharmaceuticals LP $337 22 payments
  4. Insmed, Inc. $236 13 payments
  5. Regeneron Healthcare Solutions, Inc. $142 7 payments
  6. Genzyme Corporation $131 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $113 6 payments
  8. Grifols USA, LLC $89 4 payments
  9. Verona Pharma, Inc. $80 5 payments
  10. Harmony Biosciences LLC $80 6 payments
  11. Other $590 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,308 183 payments
  2. Education $82 5 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $616 33 payments
  2. NUCALA $314 17 payments
  3. STIOLTO RESPIMAT $258 13 payments
  4. Arikayce $218 12 payments
  5. BREZTRI $201 12 payments
  6. SPIRIVA RESPIMAT $187 10 payments
  7. DUPIXENT Immunology $131 6 payments
  8. GLASSIA $113 6 payments
  9. DUPIXENT Inflammation And Immunology $89 4 payments
  10. Prolastin-C Liquid $89 4 payments
  11. Other $1,456 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

2,402

Median for Pulmonary Disease: 936

Drug cost

$808,541

Median for Pulmonary Disease: $487,987

Branded share of claims

56%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 22 $305,889
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 91 $69,806
Spiriva Respimat Tiotropium Bromide Brand 93 $65,996
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 107 $63,641
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 94 $44,621
Ozempic Semaglutide Brand 31 $35,192
Eliquis Apixaban Brand 48 $34,938
Mounjaro Tirzepatide Brand 22 $24,566
Symbicort Budesonide/Formoterol Fumarate Brand 78 $22,913
Arnuity Ellipta Fluticasone Furoate Brand 63 $21,743

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$862,353

Medicare's payments for the services billed

Medicare patients

1,292

Average age 78

Services billed

11,767

682 women, 610 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 70%
Ischemic heart disease 61%
COPD 58%
Arthritis 57%
Heart failure 54%
Chronic kidney disease 53%
Diabetes 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $89
  • GENZYME CORPORATION $61
$151 — —
WAKIX
  • Harmony Biosciences LLC $80
$80 — —
Arikayce
  • Insmed, Inc. $66
$66 — —
NUCALA
  • GlaxoSmithKline, LLC. $27
$27 — —
Ryaltris
  • Hikma Pharmaceuticals USA $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record